Pfizer Inc. (PFE)

43.51
0.30 0.69
NYSE : Health Technology
Prev Close 43.21
Open 43.10
Day Low/High 42.91 / 43.78
52 Wk Low/High 33.20 / 45.81
Volume 23.25M
Avg Volume 21.28M
Exchange NYSE
Shares Outstanding 5.78B
Market Cap 251.57B
EPS 3.60
P/E Ratio 10.86
Div & Yield 1.36 (3.08%)

Latest News

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc.

What Is the Dow Jones Industrial Average?

What Is the Dow Jones Industrial Average?

The Dow Jones Industrial Average is a price-weighted average of 30 large American publicly traded companies on the stock market.

I Can't Believe I Missed on Altria Stock

I Can't Believe I Missed on Altria Stock

Altria had been one of my staples in the past.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

Pfizer Inc. (NYSE:PFE) today announced that the U.

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Jim Cramer: Here's What I Saw That Justified Today's Rally

Jim Cramer: Here's What I Saw That Justified Today's Rally

Some groups that have been in horrendous bear market mode finally caught a bid.

Dow Closes Sharply Higher as Late Surge Pushes Stock Gains

Dow Closes Sharply Higher as Late Surge Pushes Stock Gains

The Dow Jones Industrial Average led major market indexes higher with a late surge Tuesday after closing lower during the previous session for the eighth time in 11 trading days.

Pfizer Tops Q3 Earnings Estimate, Narrows Full-Year Guidance Range

Pfizer Tops Q3 Earnings Estimate, Narrows Full-Year Guidance Range

Pfizer posts stronger-than-expected third-quarter earnings but narrows its guidance range for full-year sales.

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

Global stocks attempted yet another rebound Tuesday, with reports of direction market intervention in China supporting prices in Asia and stronger-than-expected blue chip earnings putting European bourses on solid footing following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average and a further worrying plunge in big-name tech companies.

Facebook, General Electric, Apple, BP and IGC - 5 Things You Must Know

Facebook, General Electric, Apple, BP and IGC - 5 Things You Must Know

U.S. stock futures rise modestly on Tuesday following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average; Facebook, GE, Coca-Cola and Pfizer report earnings; Apple is expected to unveil a new iPad and perhaps a new MacBook Air at an event Tuesday.

Will the Bear Win Out? What Earnings Reports to Watch This Week

Will the Bear Win Out? What Earnings Reports to Watch This Week

TheStreet takes a look at the final week of Q3 earnings.

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

PFIZER REPORTS THIRD-QUARTER 2018 RESULTS

PFIZER REPORTS THIRD-QUARTER 2018 RESULTS

Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2018 and narrowed certain 2018 financial guidance ranges.

Pfizer Announces Clinical Development Agreement With Novartis To Advance The Treatment Of NASH

Pfizer Announces Clinical Development Agreement With Novartis To Advance The Treatment Of NASH

Pfizer Inc. (NYSE:PFE) announced today that it has entered into a non-exclusive clinical development agreement with Novartis (NYSE: NVS) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH).

Be Slow to Dump Any Stock Now With a High Dividend Yield, Solid Track Record

Be Slow to Dump Any Stock Now With a High Dividend Yield, Solid Track Record

A lot of names now suddenly present as dividend plays that maybe we do not think of in that way.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.

Complete Results From First Study In Ongoing Phase 3 Program For Tanezumab Demonstrated Significant Improvement In Pain And Function In Osteoarthritis Patients

Complete Results From First Study In Ongoing Phase 3 Program For Tanezumab Demonstrated Significant Improvement In Pain And Function In Osteoarthritis Patients

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients...

Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

Pfizer Presents Overall Survival Data From PALOMA-3 Trial Of IBRANCE® (palbociclib) In Patients With HR , HER2- Metastatic Breast Cancer

Pfizer Presents Overall Survival Data From PALOMA-3 Trial Of IBRANCE® (palbociclib) In Patients With HR , HER2- Metastatic Breast Cancer

Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+),...

Pfizer Confirms to Cut Workforce by 2%

Pfizer Confirms to Cut Workforce by 2%

Pfizer is looking to cut some 1,800 workers during 2019 amid a leadership shakeup.

Trump-FOMC Blame Game Is Pointless; Safety Stocks for Crashes -- ICYMI

Trump-FOMC Blame Game Is Pointless; Safety Stocks for Crashes -- ICYMI

Here's what you need to know now for Thursday, Oct. 11.

TheStreet Quant Rating: A (Buy)